去势抵抗性前列腺癌的治疗进展  

Treatment progress on castration-resistant prostate cancer

作　　者：王晴[1] 杜君[1] 杨庆[1] Qing WANG Jun DU Qing YANG(Department of Genitourinary Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, Chin)

机构地区：[1]天津医科大学肿瘤医院泌尿肿瘤外科,国家肿瘤临床医学研究中心,天津市肿瘤防治重点实验室,天津市300060

出　　处：《中国肿瘤临床》2016年第17期766-769,共4页Chinese Journal of Clinical Oncology

基　　金：国家自然科学基金项目(编号:81502218)资助

摘　　要：去势抵抗性前列腺癌是一种致死性疾病,进展快,常伴随着转移,预后极差,死亡率接近100%,患者中位生存时间少于20个月,是前列腺癌治疗的热点和难题,其发生发展机制尚不明确。近些年来涌现出许多治疗去势抵抗性前列腺癌的新方法,包括新型雄激素受体拮抗剂、免疫治疗、紫杉烷类化疗药物、抗血管生成药物、放射性核素、骨靶向药物以及各疗法联合应用等,改善了患者的生存期。本文就去势抵抗性前列腺癌的治疗进展进行综述。Castration-resistant prostate cancer is a fatal disease with rapid progress. This malignancy usually presents with metastasis and poor prognosis. This type of disease also often causes 100% mortality, of which the median survival time is less than 20 months. Thus, treatment of castration-resistant prostate cancer remains challenging, and the underlying mechanisms of this cancer have yet to be identified. Several new therapies for castration-resistant prostate cancer have been proposed, such as androgen receptor antagonists, immunotherapeutic drugs, taxanes, antiangiogenic agents, radionuclides, and bone-targeting drugs. These therapies can improve the survival time of patients. The advances in the treatment of castration-resistant prostate cancer are briefly reviewed in this article.

关 键 词：去势抵抗性前列腺癌 内分泌治疗 放射性核素 骨靶向药物 化疗 

分 类 号：R737.25[医药卫生—肿瘤]